Intrommune Therapeutics Announces Arrival of Stuart Loesch as New CCO
08 sept. 2021 10h02 HE
|
Intrommune Therapeutics
NEW YORK, Sept. 08, 2021 (GLOBE NEWSWIRE) -- Intrommune Therapeutics, Inc., a New York-based, clinical stage biotechnology company developing a patient-friendly treatment platform for peanut and...
Intrommune Therapeutics Launches #PeanutAllergyStrong
24 août 2021 12h25 HE
|
Intrommune Therapeutics
NEW YORK, Aug. 24, 2021 (GLOBE NEWSWIRE) -- Intrommune Therapeutics, a New York-based, clinical stage biotechnology company developing a patient-friendly treatment platform for peanut and other food...
Intrommune Therapeutics Appoints Moises V. “Moe” Vela, Jr. to its Business Advisory Board
11 août 2021 13h37 HE
|
Intrommune Therapeutics
NEW YORK, Aug. 11, 2021 (GLOBE NEWSWIRE) -- Intrommune Therapeutics, a New York-based, clinical stage biotechnology company developing a patient-friendly treatment platform for peanut and other food...
Global Food Allergy and Intolerance Products Market Report 2021: Market to Reach $32 Billion by 2027 - Broad Availability of Products Encourage Market Growth
09 août 2021 08h08 HE
|
Research and Markets
Dublin, Aug. 09, 2021 (GLOBE NEWSWIRE) -- The "Food Allergy and Intolerance Products - Global Market Trajectory & Analytics" report has been added to ResearchAndMarkets.com's offering. Global...
Intrommune Therapeutics Appoints Sergi Trilla, MD, MBA to its Scientific and Business Advisory Boards
28 juil. 2021 14h10 HE
|
Intrommune Therapeutics
NEW YORK, July 28, 2021 (GLOBE NEWSWIRE) -- Intrommune Therapeutics, a New York-based, clinical stage biotechnology company developing a patient-friendly treatment platform for peanut and other food...
Intrommune Therapeutics Presents at Next Generation Food Allergy Drug Summit
22 juil. 2021 16h57 HE
|
Intrommune Therapeutics
NEW YORK, July 22, 2021 (GLOBE NEWSWIRE) -- Intrommune Therapeutics, a New York-based clinical stage biotechnology company developing a patient-friendly treatment platform for peanut and other food...
Intrommune Therapeutics to Present at BIO Digital 2021
17 juin 2021 09h11 HE
|
Intrommune Therapeutics
NEW YORK, June 17, 2021 (GLOBE NEWSWIRE) -- Intrommune Therapeutics, a New York-based clinical stage biotechnology company developing a patient-friendly treatment platform for peanut and other food...
Zoom-In on Health Equity: AAFA Asks Congress to Tackle Racial Disparities in Asthma and Allergy
30 avr. 2021 14h22 HE
|
Asthma and Allergy Foundation of America
Washington, D.C, April 30, 2021 (GLOBE NEWSWIRE) -- Each year, the Asthma and Allergy Foundation of America (AAFA) brings patient spokespeople and advocates from across the nation to Congress to...
AAFA Meets Asthma and Allergy Awareness Month with 31 DAYS OF ACTION
29 avr. 2021 14h03 HE
|
Asthma and Allergy Foundation of America
Washington, D.C, April 29, 2021 (GLOBE NEWSWIRE) -- May is National Asthma and Allergy Awareness Month. This year the Asthma and Allergy Foundation of America (AAFA) is encouraging everyone to look...
AAFA Celebrates Massive Health Policy Change; Lawmakers Pass FASTER Act Making Sesame A Major Food Allergen
14 avr. 2021 17h55 HE
|
Asthma and Allergy Foundation of America
Washington, D.C., April 14, 2021 (GLOBE NEWSWIRE) -- Today the House passed Act, S. 578/H.R.1202, otherwise known as the FASTER Act. It declares sesame the 9th major food allergen recognized by law...